Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SUM149PT Etoposide
0.0033333
Topo II
Chemotherapy
 0.9922 -0.00041
SUM149PT Etoposide
0.01
Topo II
Chemotherapy
 0.9718 0.00330
SUM149PT Etoposide
0.031667
Topo II
Chemotherapy
 0.8866 0.02150
SUM149PT Etoposide
0.1
Topo II
Chemotherapy
 0.5782 0.13581
SUM149PT Etoposide
0.31623
Topo II
Chemotherapy
 0.1686 0.36956
SUM149PT Etoposide
1.0
Topo II
Chemotherapy
 -0.0870 0.48395
SUM149PT Etoposide
3.1623
Topo II
Chemotherapy
 -0.1059 0.43245
SUM149PT Etoposide
10.0
Topo II
Chemotherapy
 -0.1961 0.57747
SUM149PT Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 1.0098 0.00203
SUM149PT Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 1.0220 0.00249
SUM149PT Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.8935 0.01252
SUM149PT Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.7798 0.04186
SUM149PT Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.3959 0.16047
SUM149PT Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.1599 0.25522
SUM149PT Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.1122 0.28597
SUM149PT Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 -0.0500 0.35673
SUM149PT Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 -0.1819 0.42667
SUM149PT Trametinib
0.0001
MEK
MAPK/nRTK
 1.0038 0.00217
SUM149PT Trametinib
0.00031623
MEK
MAPK/nRTK
 1.0601 -0.00013
SUM149PT Trametinib
0.001
MEK
MAPK/nRTK
 0.9413 0.00154
SUM149PT Trametinib
0.0031623
MEK
MAPK/nRTK
 0.8259 0.00739
SUM149PT Trametinib
0.01
MEK
MAPK/nRTK
 0.5050 0.03019
SUM149PT Trametinib
0.031623
MEK
MAPK/nRTK
 0.3640 0.06064
SUM149PT Trametinib
0.1
MEK
MAPK/nRTK
 0.2730 0.09741
SUM149PT Trametinib
0.31623
MEK
MAPK/nRTK
 0.2632 0.10341